مباشر

FierceBiotechADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect FierceBiotechADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes Clinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune Disease CellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvation CellReplaying germinal center evolution on a quantified affinity landscape CellXenophagocytosis blockade enhances interspecies chimerism FierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy Endpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetes Endpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year Endpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and more FierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs

FierceBiotech ٧ يونيو ٢٠٢٦

ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect

As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and developme...

As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche helped get the show rolling with a deep dive into their amylin analog petrelintide.